Kane Biotech Announces New Sales Representation by SLA Brands
24 April 2019 - 8:55PM
Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today announces a strategic
partnership with Schiaffino, Lasky, & Associates Inc. (SLA
Brands). SLA Brands will exclusively represent Kane Biotech’s
bluestem line of products to distributors and retailers in the
United States (US) market.
“We are extremely pleased to be working with such a
well-respected group within the pet industry and look forward
expanding the retail footprint of our bluestem line of products
across the US market,” said Marc Edwards, Kane Biotech’s CEO.
“We’ve seen tremendous growth in this line of products over the
past few months and expect SLA’s representation in a key market to
further accelerate our market expansion.”
“We look forward to representing Kane Biotech’s innovative
product line in the US. As one of the most comprehensive pet oral
care lines on the market, we anticipate strong sales of Kane’s
bluestem products,” said Bill Schiaffino, Founder and President,
SLA Brands, Inc.
About Kane Biotech Kane Biotech is a
biotechnology company engaged in the research, development and
commercialization of technologies and products that prevent and
remove microbial biofilms. The Corporation has a portfolio of
biotechnologies, intellectual property (66 patents and patents
pending, trade secrets and trademarks) and products developed by
the Corporation’s own biofilm research expertise and acquired from
leading research institutions. StrixNB(TM), DispersinB(R),
Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and
Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit www.kanebiotech.com or
contact: |
|
Marc Edwards |
|
Chief Executive Officer |
|
Kane Biotech Inc. |
|
+1 (514) 910-6991 |
medwards@kanebiotech.com |
|
|
Grant Humphrey |
|
Vice President, Sales and Business
Development |
|
Kane Biotech Inc. |
|
+1 (204) 914-5089 |
ghumphrey@kanebiotech.com |
|
|
Joe Green |
|
US. Investor Relations |
|
Edison Inc. |
|
+1 (646) 653-7030 |
jgreen@edisongroup.com |
|
|
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com.
The Company cautions that the foregoing list of factors that may
affect future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2024 to May 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From May 2023 to May 2024